SLC40A1 and neoplasm: Tumor hypoxia supports such an iron-donor phenotype by upregulating solute carrier family 40, member 1 (SLC40A1) and lipocalin 2 (LCN2) expression in TAMs, resulting in increased iron availability in the TME and improved iron uptake by malignant cells (69–71).